Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Accumulated Expenses (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Other Accumulated Expenses for 2 consecutive years, with $83000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 36.64% to $83000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83000.0 through Dec 2025, down 36.64% year-over-year, with the annual reading at $83000.0 for FY2025, 36.64% down from the prior year.
  • Other Accumulated Expenses hit $83000.0 in Q4 2025 for Xilio Therapeutics, down from $88000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $196000.0 in Q2 2025 to a low of $7000.0 in Q2 2024.